Drawing for EMPOWER PHARMA

USPTO serial 98512805

EMPOWER PHARMA

Reviewed by CopyMark Law Group

Status 654
Filing date
Status date
Registration date
—
Examiner
VALLILLO, MELISSA C
Law office
TMEG LAW OFFICE 105

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with EMPOWER PHARMA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

John A. Yates

John A. Yates Patterson + Sheridan, LLP24 Greenway PlazaSuite 1600Houston, TX 77046

Goods and services

ClassDescriptionStatusFirst use
035Supply chain management services for others in the pharmaceutical industry in the field of pharmaceuticalsACTIVE—
040Contract manufacturing of pharmaceuticals; contract manufacturing of pharmaceutical ingredients, chemical preparations and ingredients for pharmaceuticals, biopharmaceuticals, therapeutic agents, biological and biotechnological preparations, chemical preparations, and reagents for others; contract manufacturing of chemicals, biologics, preparations, and reagents for others in the field of pharmacology, microbiology, toxicology, and biotechnology; commercial production, namely, custom manufacturing of pharmaceuticalsACTIVE—
042Pharmaceutical drug development services and contract pharmaceutical drug development services; Research and development services of pharmaceutical products and preparations; Research and development services of pharmaceutical products and preparations for others; Conducting research, formulation development, scientific research in the nature of clinical trials and quality assurance for others in the pharmaceutical industry in the field of pharmaceuticals; Conducting post-marketing product support for others in the pharmaceutical industry in the field of pharmaceuticals, namely, post-market surveillance, clinical trials, and studies to further assess the safety, efficacy, or optimal use of approved products; Packaging design services in the pharmaceutical industry in the field of pharmaceuticals; Laboratory research services and contract research services, namely, analytical and microbiological testing for others in the pharmaceutical industry; Laboratory analysis for others in the field of pharmaceuticals; Laboratory research services in the fields of pharmacology, microbiology, toxicology, and biotechnology; Testing and analysis of pharmaceuticals per industry standards and for compliance with the requirements of the United States Pharmacopeia regulatory requirements; Quality control testing for others in the pharmaceutical industry; Quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of pharmacology, microbiology, toxicology, and biotechnology; Testing of pharmaceutical raw materials to determine conformity with established regulatory standardsACTIVE—
045Conducting regulatory compliance consulting for others in the pharmaceutical industry in the field of pharmaceuticalsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 22, 2026RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Sep 7, 2025RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Mar 6, 2025GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Mar 6, 2025GNSLLETTER OF SUSPENSION E-MAILED—
Mar 6, 2025CNSLSUSPENSION LETTER WRITTEN—
Feb 6, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 6, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 6, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 7, 2024GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 7, 2024GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 7, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 5, 2024DOCKASSIGNED TO EXAMINER—
Oct 9, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 7, 2024PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Apr 22, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance